<DOC>
	<DOCNO>NCT02556632</DOCNO>
	<brief_summary>This randomize pilot phase II trial study compare prophylactic topical agent reduce radiation-induced dermatitis patient non-inflammatory breast cancer breast cancer situ . The prophylactic topical agent , curcumin-based gel HPR Plus , may reduce severity radiation-induced dermatitis minimize water loss inflammation radiation therapy .</brief_summary>
	<brief_title>Prophylactic Topical Agents Reducing Radiation-Induced Dermatitis Patients With Non-inflammatory Breast Cancer Breast Cancer In Situ</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To investigate effectiveness Curcumin gel ( curcumin-based gel ) HPR Plus™ reduce radiation dermatitis breast cancer patient . SECONDARY OBJECTIVES : I . To investigate effectiveness Curcumin gel HPR Plus™ reduce pain radiation therapy ( RT ) -induced skin reaction . TERTIARY OBJECTIVES : I . To evaluate feasibility administer prophylactic topical treatment radiation dermatitis breast cancer patient receive RT . II . Identify blood biomarker correlate severity radiation dermatitis end RT biomarker response topical treatment . III . Evaluate feasibility accuracy use `` central blind reviewer '' rating radiation dermatitis severity digital photograph . OUTLINE : Patients randomize 1 3 arm . ARM I : Patients apply curcumin-based gel three time daily ( TID ) approximately every 4-6 hour begin first day radiation therapy continue 1 week completion radiation therapy . ARM II : Patients apply HPR Plus™ topically TID approximately every 4-6 hour begin first day radiation therapy continue 1 week completion radiation therapy . ARM III : Patients apply placebo gel topically TID approximately every 4-6 hour begin first day radiation therapy continue 1 week completion radiation therapy . After completion radiation therapy , patient follow 2 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Radiodermatitis</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<criteria>Subjects diagnosis noninflammatory breast cancer carcinoma situ Subjects must prescribe schedule `` conventional fractionated '' RT without concurrent chemotherapy ; bolus intensity modulate radiation therapy ( IMRT ) permit ; lymph node irradiation ( i.e. , internal mammary node , supraclavicular node , axillary node , etc ) part prescribe radiation therapy permit ; conventional fractionated radiation therapy regimens eligible study describe : Minimal ( min ) total dose : whole breast : 44 gray ( Gy ) ; breast boost : 10 Gy ; tumor bed = whole breast +/ boost : 50.0 Gy ; lymph node : 45 Gy Maximal ( max ) total dose : whole breast : 50.4 Gy ; breast boost : 20 Gy ; tumor bed = whole breast +/ boost : 66.0 Gy ; lymph node : 50.4 Gy Min dose per fraction : whole breast : 1.8 Gy ; breast boost : 2.0 Gy ; tumor bed = whole breast +/ boost : 1.8 Gy ; lymph node : 1.8 Gy Max dose per fraction : whole breast : 2.0 Gy ; breast boost : 2.0 Gy ; tumor bed = whole breast +/ boost : 2.0 Gy ; lymph node : 2.0 Gy Min # fraction : whole breast : 22 Gy ; breast boost : 5 Gy ; tumor bed = whole breast +/ boost : 25 Gy ; lymph node : 25 Gy Max # fraction : whole breast : 28 Gy ; breast boost : 10 Gy ; tumor bed = whole breast +/ boost : 36 Gy ; lymph node : 28 Gy Min # session : whole breast : 22 Gy ; breast boost : 5 Gy ; tumor bed = whole breast +/ boost : 25 Gy ; lymph node : 25 Gy Max # session : whole breast : 28 Gy ; breast boost : 10 Gy ; tumor bed = whole breast +/ boost : 36 Gy ; lymph node : 28 Gy Subjects may may surgery ( lumpectomy mastectomy ) prior RT ; ( NOTE : surgery required eligibility ) Subjects may chemotherapy prior radiation ; minimum two week require end chemotherapy start RT Subjects may currently prescribe hormone treatment Herceptin therapy Subjects must able read , speak , understand English Subjects must ability understand willingness sign write informed consent document Subjects must agree use topical agent skin radiation treatment area course trial ; subject use topical agent study ( i.e. , topical intervention standard care agent ) supply study personnel and/or treat physician Pregnant female ineligible ; subject childbearing potential ask pregnant could pregnant ; patient must respond `` '' continue radiation participate clinical study Subjects bilateral breast cancer eligible Subjects receive shortcourse fractionation radiation therapy ( i.e. , 16 session 20 session 2.4 2.6 Gy fraction per session , without boost ) Subject currently antiEGFR ( human epidermal growth factor receptor ) therapy , Iressa ( gefitinib ) Erbitux ( cetuximab , C225 ) Previous radiation chest breast Subjects breast reconstruction prior RT Previous diagnosis radiosensitivity disorder ( i.e. , ataxia telangiectasia ) Previous diagnosis collagen vascular disorder vasculitis Presence unhealed surgical wound chest breast region and/or breast infection Current daily application prescribe topical product skin within RT area unrelated skin condition discontinue participation clinical trial Presence active dermatological issue radiation treatment area ( i.e. , fungal skin infection , dermatitis , psoriasis plaque , etc )</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>